Given the PD-L1 positivity in the rectal lesion and high tumor mutation burden and MSI-H in the gastric lesion, after comprehensive discussions with the patient, it was decided to supplement the chemotherapy regimen with immunotherapy. The gene discussed is CD274; the disease is neoplasm.